Filing Flows › Companies › AbCellera Biologics › Timeline
AbCellera Biologics stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions+162.2% to $11.88
AbCellera Biologics (ABCL) stock rose 162% over the last 252 sessions, to $11.88. On the way it reported 4 quarters, its insiders filed 9 open-market trades, and the company filed 5 material 8-Ks. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Aug 24, 2026 | Insider buy | Hayden Michael R bought $570K | −6.5% (−6.2% vs SPY) | +0.3% (−0.2% vs SPY) | +11.1% (+9.9% vs SPY) |
| Aug 18, 2026 | Insider buy | Montalbano John S. bought $110K | −0.7% (0.0% vs SPY) | −5.4% (−4.2% vs SPY) | +4.1% (+6.6% vs SPY) |
| Aug 14, 2026 | Insider buy | Booth Andrew bought $384K | +3.7% (+3.9% vs SPY) | +5.3% (+7.3% vs SPY) | +1.8% (+4.0% vs SPY) |
| Aug 13, 2026 | 8-K | Material definitive agreement | +3.7% (+3.9% vs SPY) | +5.3% (+7.3% vs SPY) | +1.8% (+4.0% vs SPY) |
| Aug 12, 2026 | Insider buy | Hayden Michael R bought $481K | +5.9% (+5.7% vs SPY) | +13.0% (+13.4% vs SPY) | +6.9% (+8.6% vs SPY) |
| Aug 5, 2026 | Earnings | Earnings: missed the EPS estimate by -9.1% | −2.8% (−2.6% vs SPY) | +47.2% (+47.3% vs SPY) | +62.4% (+63.2% vs SPY) |
| Jul 6, 2026 | 8-K | Directors and officers: departures, appointments, pay | −3.0% (−3.9% vs SPY) | −17.6% (−19.0% vs SPY) | −33.0% (−34.7% vs SPY) |
| Jun 5, 2026 | 8-K | Directors and officers: departures, appointments, pay | −12.5% (−9.9% vs SPY) | −19.0% (−16.4% vs SPY) | +18.8% (+19.8% vs SPY) |
| May 14, 2026 | Insider buy | Montalbano John S. bought $95K | −8.1% (−8.9% vs SPY) | −4.3% (−4.1% vs SPY) | +9.4% (+9.5% vs SPY) |
| May 11, 2026 | Earnings | Earnings: beat the EPS estimate by 29.1% | +0.2% (0.0% vs SPY) | −24.8% (−25.0% vs SPY) | +1.1% (+1.2% vs SPY) |
| Feb 27, 2026 | Insider buy | Thermopylae Holdings Ltd. bought $131K | +0.6% (+1.0% vs SPY) | 0.0% (+1.2% vs SPY) | −9.4% (−1.3% vs SPY) |
| Feb 27, 2026 | Insider buy | Booth Andrew bought $146K | +0.6% (+1.0% vs SPY) | 0.0% (+1.2% vs SPY) | −9.4% (−1.3% vs SPY) |
| Feb 26, 2026 | Insider buy | Thermopylae Holdings Ltd. bought $580K | +11.8% (+12.4% vs SPY) | +12.9% (+14.1% vs SPY) | +4.9% (+11.8% vs SPY) |
| Feb 24, 2026 | Earnings | Earnings: beat the EPS estimate by 83.3% | +6.1% (+5.4% vs SPY) | +23.2% (+22.6% vs SPY) | +8.8% (+13.0% vs SPY) |
| Nov 28, 2025 | 8-K | Change in auditor | +2.4% (+1.9% vs SPY) | +0.3% (−0.4% vs SPY) | −5.1% (−6.6% vs SPY) |
| Nov 26, 2025 | Insider buy | Montalbano John S. bought $178K | +0.6% (−0.1% vs SPY) | −3.7% (−5.0% vs SPY) | −1.1% (−3.7% vs SPY) |
| Nov 12, 2025 | 8-K | Directors and officers: departures, appointments, pay | −1.0% (−1.1% vs SPY) | −9.1% (−5.7% vs SPY) | −7.0% (−7.9% vs SPY) |
| Nov 6, 2025 | Earnings | Earnings: missed the EPS estimate by -17.3% | −3.5% (−2.4% vs SPY) | −16.7% (−17.5% vs SPY) | −27.6% (−28.8% vs SPY) |
Insiders’ record here
In the year on the chart, AbCellera Biologics' insiders reported 9 open-market buys ($2.7M) and 0 sales ($0). Of the 5 old enough to score, 5 were followed by the stock doing what the trade implied over the next 63 sessions (beating SPY after a buy, lagging it after a sale); the median excess return after a buy was +60.6% and after a sale —.
Across the whole universe (19,782 scored trades), insider buys beat the market 46% of the time and sales were followed by a lagging stock 61% of the time; buys of $1M or more 39%. Every pattern →
What this kind of 8-K usually did
| Item | 8-Ks | Next session, median | Up next session | 21 sessions, median | Typical size |
|---|---|---|---|---|---|
| 5.02 Directors and officers: departures, appointments, pay | 39,174 | −0.1% | 48% | +0.7% | ±1.4% |
| 4.01 Change in auditor | 538 | 0.0% | 49% | −0.1% | ±1.7% |
| 1.01 Material definitive agreement | 23,525 | 0.0% | 51% | +1.0% | ±1.4% |
Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →
Report card: every quarter against the estimate → AbCellera Biologics: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.